CARMAT |
Market Closed -
Other stock markets
|
After market 01:49:05 pm | |||
| 2.9 EUR | -3.65% |
|
2.918 | +0.62% |
| Mar. 25 | Carmat: final agreement with creditors | CF |
| Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
| Sales 2023 | 2.8M 3M | Sales 2024 * | 23.05M 24.68M | Capitalization | 74.59M 79.88M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -56.76M | Net income 2024 * | -38M -40.69M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.15M | Net Debt 2024 * | 68.9M 73.79M | EV / Sales 2024 * | 6.23 x |
| P/E ratio 2023 * |
-1.45
x | P/E ratio 2024 * |
-2.54
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | -2.16% | ||
| 1 week | -22.09% | ||
| Current month | -28.43% | ||
| 1 month | -26.01% | ||
| 3 months | -27.46% | ||
| 6 months | -13.13% | ||
| Current year | -56.04% |
1 week
2.90
3.92
1 month
2.904.18
Current year
2.907.72
1 year
2.909.99
3 years
2.9031.70
5 years
2.9036.00
10 years
2.9096.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 2.9 | -3.65% | 79 790 |
| 24-04-30 | 3.01 | -1.31% | 30,219 |
| 24-04-29 | 3.05 | -3.17% | 89,477 |
| 24-04-26 | 3.15 | -2.63% | 63,346 |
| 24-04-25 | 3.235 | -6.50% | 146,450 |
Real-time Euronext Paris, May 02, 2024 at 08:58 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.01
EUR
Average target price
14.22
EUR
Spread / Average Target
+372.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.04% | 79.67M | |
| -8.69% | 10.63B | |
| +2.17% | 8.92B | |
| +19.94% | 7.39B | |
| +24.43% | 4.96B | |
| +7.46% | 3.41B | |
| -1.11% | 3.04B | |
| -5.07% | 2.23B | |
| -4.22% | 2.13B | |
| -20.87% | 1.84B |
- Stock Market
- Equities
- ALCAR Stock
